- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.01. | NewcelX Ltd.: NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | 524 | PR Newswire | ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine... ► Artikel lesen | |
| 12.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX: Patent für neurologische Therapien in China veröffentlicht | 4 | Investing.com Deutsch | ||
| 11.12.25 | NewcelX patent for neurological disease treatments published in China | 2 | Investing.com | ||
| 17.11.25 | NewcelX appoints ALS specialist to scientific advisory board | 1 | Investing.com | ||
| 17.11.25 | NewcelX Ltd.: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute | 181 | PR Newswire | ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 17.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | Neurology expert Prof. Ben-Hur joins NewcelX scientific board | 2 | Investing.com | ||
| 04.11.25 | NewcelX Ltd.: NewcelX CEO Issues Letter to Shareholders | 216 | PR Newswire | ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. | 288 | PR Newswire | ZURICH, Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger / Combined Company Re-Named NewcelX Ltd. | 626 | PR Newswire | Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"
ZURICH and NESS ZIONA... ► Artikel lesen | |
| 30.10.25 | NSE/A - NLS Pharmaceutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10.25 | NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 718 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system... ► Artikel lesen | |
| 29.10.25 | NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 326 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,985 | -0,82 % | Danaher mit Paukenschlag - Qiagen unter Druck | Der Life-Science-Riese Danaher will für knapp zehn Milliarden Dollar die Masimo Corporation einverleiben. Mit dem Zukauf verstärken sich die Amerikaner im Bereich nichtinvasiver Technologien zur Patientenüberwachung.... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,100 | -1,35 % | ADMA Biologics, Inc.: ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | ||
| RECURSION PHARMACEUTICALS | 3,420 | -8,06 % | Aktien New York Ausblick: Gewinne erwartet - Nvidia führt Tech-Riesen an | NEW YORK (dpa-AFX) - Nach ihrem verhaltenen Auftakt in die verkürzte Börsenwoche dürften die US-Aktienmärkte am Mittwoch einen Erholungsversuch starten. Bevor am Abend das Sitzungsprotokoll der US-Notenbank... ► Artikel lesen | |
| BIONTECH | 93,45 | +2,19 % | Biotech erwacht: Steht die nächste Rallye für BioNTech, BioNxt und Mesoblast bevor? | ||
| ALUMIS | 27,970 | -4,23 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,200 | -1,21 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| ZENAS BIOPHARMA | 25,880 | -4,22 % | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| PRAXIS PRECISION MEDICINES | 336,17 | +1,56 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 29,160 | -15,21 % | Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy | ||
| AVIDITY BIOSCIENCES | 72,85 | -0,04 % | Avidity: Vielversprechende Studienergebnisse für Medikament gegen myotone Dystrophie | ||
| EDGEWISE THERAPEUTICS | 29,310 | -0,68 % | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,42 | +1,02 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| ANNEXON | 4,900 | -3,92 % | Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ||
| CARDIO DIAGNOSTICS | 2,860 | +27,68 % | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 15,950 | +0,50 % | Summit Therapeutics Q4 2025 Earnings Preview |
NEWCELX LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.